Developer of advanced cancer treatment intended for targeting hard-to-treat cancers. The company leverages antibody drug conjugates to develop next-generation treatments, utilizing both novel and clinically validated monoclonal antibodies armed with proprietary payloads, enabling healthcare market to address unmet medical needs in solid tumors and liquid cancers through innovative and effective therapies.